Sonoma Pharmaceuticals WKN: A2PMPH ISIN: US83558L2043 Forum: Aktien Thema: Hauptdiskussion

Veterinarian-strength MicrocynVS is formulated for the management of wound, skin, ear and eye afflictions in all animal species. MicrocynVS products are designed to assist the animal's body in its own healing process. Many of the wounds, lacerations, rashes and infections encountered by veterinarians can be addressed with MicrocynVS. Additionally, Sonoma has entered into a non-exclusive distribution agreement with DV Medical Supply for the sale of MicrocynVS products in veterinarian clinics and practices throughout the United States. DV Medical Supply is a total solution provider to licensed veterinary and medical professionals. They are well known for their extensive selection of quality medical supplies and pharmaceuticals. For the next several months, DV Medical Supply will be rolling out MicrocynVS to over 700 vet offices throughout the United States. "We expect the line of MicrocynVS products to become an integral part of veterinary care," said Josh Hyams, CMO and owner of DV Medical Supply. "For veterinarians, finding a superior cost-effective product that significantly decreases healing time and is safe for patients is key. Since MicrocynVS can be used for eye, ear, wound and skin issues, vets no longer need to stock four different products, eliminating redundant stock. Our goal is to provide veterinarians with high quality products with the ability to generate income for their practice. Essentially, we want to level the playing field and MicrocynVS has the potential to do just that." "We are pleased to bring MicrocynVS to veterinarians through our partner, DV Medical Supply," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "MicrocynVS is one of the most powerful hypochlorous acid formulations on the market today. MicrocynVS safely eradicates most bacteria, viruses, fungi and spores to 99.9999% in just thirty seconds. We believe MicrocynVS will make a huge positive impact to veterinarian care and the animal patients they care for. Our proprietary Microcyn® technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety."

WOODSTOCK, GA / ACCESSWIRE / August 2, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched a MicrocynVS® line of products exclusively for veterinarians.

Lieben wir

👍

Top Kursanstieg heute!

😂😂

Viel zu spät

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19

Bewegt sich...

Zurück im Niemandsland. Lauchaktie

Sagen wir mal so es wird etwas besser, aber zum glücklich Sein brauchen wir noch etwas mehr.

Sonoma mach mich glücklich....

Ist man gar nicht gewohnt 🙈😅 hab ein EK von 5,20€ hoffe der wird dieses Jahr erreicht haha

Nein, lediglich Verluste etwas aufgeholt. Stark wäre mal über 4€

Sehr stark....

Stabil Stabiler Zwischendurch ein debiler Und wieder stabil